Otsuka Holdings Dirección

Dirección controles de criterios 3/4

El CEO de Otsuka Holdings' es Tatsuo Higuchi, nombrado en Jul 2008, tiene una permanencia de 16.08 años. posee directamente un 0.031% de las acciones de la empresa, con un valor de €7.84M. La antigüedad media del equipo directivo y de la junta directiva es de 2.6 años y 6.4 años, respectivamente.

Información clave

Tatsuo Higuchi

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	16.3yrs
Participación del CEO	0.03%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	6.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Tatsuo Higuchi en comparación con los beneficios de Otsuka Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	JP¥127b
Mar 31 2024	n/a	n/a	JP¥138b
Dec 31 2023	n/a	n/a	JP¥122b
Sep 30 2023	n/a	n/a	JP¥185b
Jun 30 2023	n/a	n/a	JP¥167b
Mar 31 2023	n/a	n/a	JP¥172b
Dec 31 2022	JP¥280m	JP¥156m	JP¥134b
Sep 30 2022	n/a	n/a	JP¥110b
Jun 30 2022	n/a	n/a	JP¥104b
Mar 31 2022	n/a	n/a	JP¥104b
Dec 31 2021	JP¥283m	JP¥156m	JP¥125b
Sep 30 2021	n/a	n/a	JP¥147b
Jun 30 2021	n/a	n/a	JP¥153b
Mar 31 2021	n/a	n/a	JP¥155b
Dec 31 2020	JP¥316m	JP¥156m	JP¥148b
Sep 30 2020	n/a	n/a	JP¥143b
Jun 30 2020	n/a	n/a	JP¥146b
Mar 31 2020	n/a	n/a	JP¥146b
Dec 31 2019	JP¥244m	JP¥156m	JP¥127b
Sep 30 2019	n/a	n/a	JP¥116b
Jun 30 2019	n/a	n/a	JP¥86b
Mar 31 2019	n/a	n/a	JP¥79b
Dec 31 2018	JP¥178m	JP¥156m	JP¥82b
Sep 30 2018	n/a	n/a	JP¥117b
Jun 30 2018	n/a	n/a	JP¥134b
Mar 31 2018	n/a	n/a	JP¥114b
Dec 31 2017	JP¥298m	JP¥157m	JP¥112b

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Tatsuo es razonable en comparación con empresas de tamaño similar en el mercado German.

Compensación vs. Ingresos: La compensación de Tatsuo ha sido consistente con los resultados de la empresa en el último año.

CEO

Tatsuo Higuchi (74 yo)

16.3yrs

Permanencia

JP¥280,000,000

Compensación

Mr. Tatsuo Higuchi has been the President, Chief Executive Officer and Representative Director of Otsuka Holdings Co., Ltd. since July 2008. Mr. Higuchi has been the Chairman of Otsuka Pharmaceutical Co.,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Tatsuo Higuchi	CEO, President & Representative Director	16.3yrs	JP¥280.00m	0.031% ¥ 8.8m
Makoto Inoue	COO & Representative Director	less than a year	JP¥154.00m	0.0089% ¥ 2.5m
Yoshiro Matsuo	Executive Deputy President & Executive Director	2.6yrs	JP¥128.00m	0.012% ¥ 3.4m
Masayuki Kobayashi	Executive Director	7.6yrs	JP¥138.00m	0.014% ¥ 3.9m
Yuko Makino	CFO & Executive Director	6.6yrs	sin datos	0.0041% ¥ 1.1m
Tomohiro Emura	Vice President of Investor Relations	less than a year	sin datos	sin datos
Akiko Ryu	Senior VP & Director of Human Resource Planning Department	2.8yrs	sin datos	sin datos
Noriko Tojo	Executive Director	6.6yrs	JP¥104.00m	0.011% ¥ 3.1m
Shuichi Takagi	Executive Director	5.6yrs	sin datos	0.0054% ¥ 1.5m
Chiaki Sakurai	Senior Vice President of Nutraceutical Business	2.8yrs	sin datos	sin datos
Shigeko Takahashi	Senior VP and GM of Nutraceutical Business	2.8yrs	sin datos	sin datos
Manabu Kawata	Senior Vice President of Business Development Department	2.8yrs	sin datos	sin datos

2.8yrs

Permanencia media

63yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de OS1 se considera experimentado (2.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Tatsuo Higuchi	CEO, President & Representative Director	16.3yrs	JP¥280.00m	0.031% ¥ 8.8m
Makoto Inoue	COO & Representative Director	4.6yrs	JP¥154.00m	0.0089% ¥ 2.5m
Yoshiro Matsuo	Executive Deputy President & Executive Director	no data	JP¥128.00m	0.012% ¥ 3.4m
Masayuki Kobayashi	Executive Director	7.6yrs	JP¥138.00m	0.014% ¥ 3.9m
Yuko Makino	CFO & Executive Director	6.6yrs	sin datos	0.0041% ¥ 1.1m
Noriko Tojo	Executive Director	6.6yrs	JP¥104.00m	0.011% ¥ 3.1m
Shuichi Takagi	Executive Director	5.6yrs	sin datos	0.0054% ¥ 1.5m
Ichiro Otsuka	Chairman	16.3yrs	JP¥240.00m	1.45% ¥ 410.2m
Yukio Matsutani	Independent Outside Director	8.6yrs	sin datos	sin datos
Ko Sekiguchi	Independent Outside Director	6.6yrs	sin datos	sin datos
Yozo Toba	Chairman of Audit & Supervisory Board Member	6.6yrs	sin datos	0.0013% ¥ 366.7k
Yoshihisa Aoki	Independent Outside Director	5.6yrs	sin datos	sin datos

6.6yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de OS1 se considera experimentada (6.3 años de antigüedad promedio).

Otsuka Holdings Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 28, 2024

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 30, 2023

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 30, 2021

Recent updates

Now 23% undervalued

First half dividend of JP¥60.00 announced

Second quarter 2024 earnings released: EPS: JP¥56.04 (vs JP¥75.85 in 2Q 2023)

Otsuka Holdings Co., Ltd. (TSE:4578) announces an Equity Buyback for 10,000,000 shares, representing 1.84% for ¥50,000 million.

Otsuka Holdings Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Year 2026

First quarter 2024 earnings released: EPS: JP¥143 (vs JP¥113 in 1Q 2023)

Now 21% undervalued

Final dividend of JP¥60.00 announced

Now 21% undervalued

Otsuka Holdings Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings released: EPS: JP¥224 (vs JP¥247 in FY 2022)

Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024

Otsuka Holdings Co., Ltd. Revises Dividend for the Full Year Ending December 31, 2023, Payable on March 29 , 2024

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ended December 31, 2023

Upcoming dividend of JP¥50.00 per share at 1.9% yield

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Third quarter 2023 earnings released: EPS: JP¥109 (vs JP¥76.07 in 3Q 2022)

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Now 20% undervalued

Second quarter 2023 earnings released: EPS: JP¥75.86 (vs JP¥85.70 in 2Q 2022)

Otsuka Holdings Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half of Fiscal Year 2023

Otsuka Pharmaceutical Co., Ltd. Announces Positive Results of Phase III Trial in Japan Showing Reduced Agitation in Patients with Alzheimer's Dia Treated with Brexpiprazole

Upcoming dividend of JP¥50.00 per share at 1.8% yield

Otsuka Holdings Co., Ltd. to Report Q2, 2023 Results on Jul 31, 2023

First quarter 2023 earnings released: EPS: JP¥113 (vs JP¥42.88 in 1Q 2022)

Now 20% undervalued after recent price drop

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 30, 2023

Full year 2022 earnings released: EPS: JP¥247 (vs JP¥231 in FY 2021)

Otsuka Holdings Co., Ltd. Provides Dividend Guidance for Fiscal Year Ending 2023

Otsuka Pharmaceutical Co., Ltd. (Otsuka) Files an Application in Japan for an Additional Indication for Rexulti

Now 23% undervalued after recent price drop

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2022 Results on Feb 14, 2023

Upcoming dividend of JP¥50.00 per share

Now 21% undervalued after recent price drop

Otsuka Medical Devices Co., Ltd. and Recor Medical, Inc. Announce Submission of Application for Pre-Market Approval of the Paradise uRDN to the U.S. FDA

Third quarter 2022 earnings released: EPS: JP¥76.07 (vs JP¥64.97 in 3Q 2021)

Otsuka Holdings Co., Ltd. Revises Consolidated earnings Guidance for the Fiscal Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. Revises Consolidated Earrings Guidance for the Fiscal Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month by Otsuka America Pharmaceutical, Inc

Second quarter 2022 earnings released: EPS: JP¥85.70 (vs JP¥86.15 in 2Q 2021)

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ended June 30, 2022

Otsuka Holdings Co., Ltd. to Report Q2, 2022 Results on Jul 29, 2022

Upcoming dividend of JP¥50.00 per share

First quarter 2022 earnings released: EPS: JP¥42.88 (vs JP¥82.39 in 1Q 2021)

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter of Fiscal Year Ending December 31, 2022; Provides Earnings Guidance for the Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. to Report Q1, 2022 Results on May 13, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter and Full Year of Fiscal Ending December 31, 2022

Otsuka Holdings Co., Ltd. Revises Earnings Guidance for the Fiscal Year 2021

Upcoming dividend of JP¥50.00 per share

Third quarter 2021 earnings released: EPS JP¥64.97 (vs JP¥75.52 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥86.15 (vs JP¥90.54 in 2Q 2020)

Upcoming dividend of JP¥50.00 per share

First quarter 2021 earnings released: EPS JP¥82.39 (vs JP¥69.54 in 1Q 2020)

Revenue misses expectations

Full year 2020 earnings released: EPS JP¥273 (vs JP¥235 in FY 2019)

New 90-day low: €32.60

Full year 2020 earnings released: EPS JP¥273 (vs JP¥235 in FY 2019)

Revenue misses expectations

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 30, 2021

New 90-day high: €37.00

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2020 Results on Feb 12, 2021

Revenue beats expectations

Third quarter 2020 earnings released: EPS JP¥75.52

New 90-day low: €32.00